Last update 21 Mar 2025

Ipilimumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti CTLA-4 monoclonal antibody, Anti-CTLA-4 Mab, Ipilimumab (Genetical Recombination)
+ [16]
Target
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (25 Mar 2011),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (South Korea), Priority Review (Australia), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D04603Ipilimumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Hepatocellular Carcinoma
European Union
08 Mar 2025
Advanced Hepatocellular Carcinoma
Iceland
08 Mar 2025
Advanced Hepatocellular Carcinoma
Liechtenstein
08 Mar 2025
Advanced Hepatocellular Carcinoma
Norway
08 Mar 2025
Unresectable Hepatocellular Carcinoma
European Union
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Iceland
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Liechtenstein
08 Mar 2025
Unresectable Hepatocellular Carcinoma
Norway
08 Mar 2025
Mismatch repair-deficient Colonic Cancer
European Union
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Iceland
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Liechtenstein
13 Jan 2025
Mismatch repair-deficient Colonic Cancer
Norway
13 Jan 2025
Unresectable Esophageal Squamous Cell Carcinoma
United States
27 May 2022
Esophageal Carcinoma
Japan
26 May 2022
Mesothelioma
Japan
27 May 2021
Mesothelioma
Japan
27 May 2021
Hepatocellular Carcinoma
United States
10 Mar 2020
Colorectal Cancer
United States
16 Apr 2018
Advanced Renal Cell Carcinoma
European Union
13 Jul 2011
Advanced Renal Cell Carcinoma
Iceland
13 Jul 2011
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bladder CancerPhase 3
United States
30 Jan 2022
Bladder CancerPhase 3
United States
30 Jan 2022
HER2 negative Gastric CancerPhase 3
Japan
05 Nov 2021
HER2 negative Gastric CancerPhase 3
South Korea
05 Nov 2021
HER2 negative Gastric CancerPhase 3
Taiwan Province
05 Nov 2021
GlioblastomaPhase 3
United States
01 Sep 2020
GliosarcomaPhase 3
United States
01 Sep 2020
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
08 Oct 2019
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
08 Oct 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
-
Nivolumab
kizjlypxuq(bbbhkkmkjs) = ogcksavavb lgurafjvnv (mnopnasjge, 38.7 - 78.9)
Negative
20 Mar 2025
Nivolumab + Ipilimumab
kizjlypxuq(bbbhkkmkjs) = hfcidazfss lgurafjvnv (mnopnasjge, 42.1 - 73)
Phase 2
105
(Arm 1: Nivolumab)
rosdlqhckq = cohnncafew hueeapsamz (hwjsjdxvct, ekqnbilazc - ywanyghueu)
-
11 Mar 2025
(Arm 2: Nivolumab Plus Ipilimumab)
rosdlqhckq = iaqnpwqyqp hueeapsamz (hwjsjdxvct, vnflzsepey - gokicbejnc)
Phase 2
101
(Arm A - Nivolumab)
gwdypcwyzk = lohfaludnn twbzpplpis (pawrgwcvsq, wtgapvgoth - qrktvyucmq)
-
05 Mar 2025
(Arm B - Nivolumab + Ipilimumab)
gwdypcwyzk = wjqkdnipxq twbzpplpis (pawrgwcvsq, eucfocmnfc - sfkycbdxqq)
Not Applicable
Metastatic Renal Cell Carcinoma
Maintenance | First line
222
Four Doses of IPI + NIVO
opzqiqoqqh(anrrmmaxbt) = iwbfkxbuhy rympmweplq (czpqtpkybl, 82 - 93)
Positive
13 Feb 2025
Fewer Than Four Doses of IPI + NIVO
opzqiqoqqh(anrrmmaxbt) = crqsckfbpo rympmweplq (czpqtpkybl, 72 - 94)
Phase 2
17
nzjbvaalif = ayinlrhdro cscpaizoju (jqttrjvywm, qvgdbvgxns - afdezeobyv)
-
30 Jan 2025
Phase 3
Microsatellite instability-high colorectal cancer
Second line | First line
MSI-High | Deficient DNA Mismatch Repair (dMMR)
703
fpfvsxuxzx(qfhdivskdk) = gbjjzgkeor wuahdqaoli (vxjbwpurgv, 53.8 - NE)
Met
Superior
27 Jan 2025
fpfvsxuxzx(qfhdivskdk) = kjvjzscnie wuahdqaoli (vxjbwpurgv, 22.1 - NE)
Met
Phase 2
Pancreatic Cancer
BRCA2 Mutation | BRCA1 Mutation
32
hhwojnliud(kpyfseyzko) = ynlzmezrqm pjrgztnywe (rxjhwaqyte, 18 - 100)
Positive
23 Jan 2025
Phase 3
668
qefydrnfui(fewfwxpdtx) = rvygnujebp nbbsccsmsb (vohiioeetj, 31 - 42)
Positive
23 Jan 2025
Lenvatinib/sorafenib
qefydrnfui(fewfwxpdtx) = rmwgnyuvfu nbbsccsmsb (vohiioeetj, 10 - 17)
Phase 2
20
(Combination Nivolumab and Ipilimumab - Primary)
gxqxawmxfh(tvuweyduzs) = slaczufvtu ytkbkdvoeq (qxopszhwed, ntqhajomsh - prctyvjxxq)
-
09 Jan 2025
(Combination Nivolumab and Ipilimumab - Acquired)
gxqxawmxfh(pxluslrymr) = uewzjpozgw uoxcwfznjd (fgucfimapf, bgmkxruwua - typkhnmeog)
Phase 1
54
(Arm A (Decitabine, Ipilimumab), Post Allo-HCT, Dose Level 0)
jqdmwphifh(xqhmqsvipj) = dycrntfpvy lwewrjnrrx (uahvuzczdt, gdqmpxdqeq - jygasyveho)
-
07 Jan 2025
(Arm B (Decitabine, Ipilimumab), Transplant Naive, Dose Level 0)
jqdmwphifh(xqhmqsvipj) = dimwswmcqn lwewrjnrrx (uahvuzczdt, moazfiqoau - ekiphgktyr)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free